Clinical Outcomes after Treating Acute Coronary Syndrome Patients with a Drug-Eluting Stent: Results from REWARDS-EMI (Endeavor® for Myocardial Infarction Registry)

Cardiovascular Revascularization Medicine

Volumn 14, Issue 3, 2013, Pages 128-133

  Dvir, Danny ^a   Barbash, Israel M ^a   Torguson, Rebecca ^a   Badr, Salem ^a   Sardi, Gabriel L ^a   Laynez Carnicero, Ana ^a   Ben Dor, Itsik ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Drug eluting stent; Major adverse cardiac events

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE DURATION; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; DISEASE-FREE SURVIVAL; DISTRICT OF COLUMBIA; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879264922     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2013.01.001     Document Type: Article

References (21)

1. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001, 104:852-855.
2. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
3. Mahmoudi M., Delhaye C., Waksman R. Safety and efficacy of drug-eluting stents and bare metal stents in acute coronary syndrome. Cardiovasc Revasc Med 2011, 12:385-390.
4. Slottow T.L., Steinberg D.H., Roy P., Javaid A., Buch A.N., Okabe T., et al. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med 2008, 9:24-28.
5. Kimura T., Morimoto T., Kozuma K., Honda Y., Kume T., Aizawa T., et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010, 122:52-61.
6. Holmes D.R. Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents. Rev Cardiovasc Med 2007, 8(Suppl 1):S11-S18.
7. Chen Y.W., Smith M.L., Sheets M., Ballaron S., Trevillyan J.M., Burke S.E., et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol 2007, 49:228-235.
8. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Münzel T., et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006, 114:798-806.
9. Byrne R.A., Kastrati A., Tiroch K., Schulz S., Pache J., Pinieck S., et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 2010, 55:2536-2543.
10. Nakazawa G., Finn A.V., John M.C., Kolodgie F.D., Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007, 100:36M-44M.
11. Kim J.S., Jang I.K., Fan C., Kim T.H., Kim J.S., Park S.M., et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009, 2:1240-1247.
12. Kandzari D.E., Leon M.B., Popma J.J., Fitzgerald P.J., O'Shaughnessy C., Ball M.W., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006, 48:2440-2447.
13. Kandzari D.E., Mauri L., Popma J.J., Turco M.A., Gurbel P.A., Fitzgerald P.J., et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2011, 4:543-550.
14. Kim J.H., Park K.W., Lim W.H., Shin D.H., Na S.H., Koo B.K., et al. Comparison of two-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice. Catheter Cardiovasc Interv 2011, [Epub ahead of print].
15. Leon M.B., Mauri L., Popma J.J., Cutlip D.E., Nikolsky E., O'Shaughnessy C., et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010, 55:543-554.
16. Rasmussen K., Maeng M., Kaltoft A., Thayssen P., Kelbaek H., Tilsted H.H., et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010, 375:1090-1099.
17. Camenzind E., Wijns W., Mauri L., Kurowski V., Parikh K., Gao R., et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012, 380:1396-1405. PROTECT Steering Committee and Investigators.
18. von Birgelen C., Basalus M.W., Tandjung K., van Houwelingen K.G., Stoel M.G., Louwerenburg J.H., et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012, 59:1350-1361.
19. Serruys P.W., Silber S., Garg S., van Geuns R.J., Richardt G., Buszman P.E., et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010, 363:136-146.
20. Laynez A., Sardi G., Hauville C., Barbash I.M., Pakala R., Torguson R., et al. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population. Catheter Cardiovasc Interv 2012, [Epub ahead of print].
21. Hanna N.N., Gaglia M.A., Torguson R., Ben-Dor I., Gonzalez M.A., Collins S.D., et al. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 2010, 106:504-510.